Product Information
CLARAVIS 30 MG CAPSULE is a generic product labeled by Teva Pharmaceuticals USA Inc., priced at $2.1254 per EA under NDC 00555105686. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on Apr 11, 2003. Its Orange Book therapeutic-equivalence code is AB1 — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
30 mg/1
Manufacturer
Teva Pharmaceuticals USA Inc.NDC
00555105686
Classification
Generic
Dosage Form
CAPSULE, LIQUID FILLED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ISOTRETINOINApproval Type
Generic (ANDA)
FDA Application
ANDA076135FDA Approved
4/11/2003
TE Code
AB1
On Market Since
5/18/2006
Pharmacological Classes
Price Statistics
The NADAC for CLARAVIS 30 MG CAPSULE has been published 671 times since Nov 28, 2013, and over the history we have for it it has declined 82.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $2.1254 per EA |
|---|---|
| All-time high | $12.2436 (Oct 15, 2014) |
| All-time low | $1.8937 (Feb 18, 2026) |
| 52-week high | $2.3030 |
| 52-week low | $1.8937 |
| Median price | $5.0281 |
| Average price | $5.9428 |
| Largest weekly change | +44.9% (Aug 21, 2024) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 6 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Teva Pharmaceuticals USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Isotretinoin market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Retinoid class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CLARAVIS 30 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for CLARAVIS 30 MG CAPSULE, manufactured by Teva Pharmaceuticals USA Inc., is $2.1254 per EA (NDC 00555105686), effective Sep 30, 2026.
How has the price of CLARAVIS 30 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for CLARAVIS 30 MG CAPSULE has declined 82.6%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for CLARAVIS 30 MG CAPSULE?
Since Nov 28, 2013, the NADAC for CLARAVIS 30 MG CAPSULE has ranged from a low of $1.8937 (Feb 18, 2026) to a high of $12.2436 (Oct 15, 2014), with a median of $5.0281 per EA.
Are there cheaper alternatives to CLARAVIS 30 MG CAPSULE?
6 manufacturers publish a NADAC-priced product with the same active ingredient and strength as CLARAVIS 30 MG CAPSULE in a comparable dosage form, but none are currently priced below it.
Who manufactures CLARAVIS 30 MG CAPSULE?
CLARAVIS 30 MG CAPSULE (NDC 00555105686) is labeled by Teva Pharmaceuticals USA Inc., and CMS classifies it as a generic product.